Corporate Profile

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Recent News

  • Jan 03, 2019

    Sets the Stage for Phase 3 Clinical Trial in 2019 Phase 2 clinical trial confirmed Phase 1/2 results, again demonstrating improved immune responses over Fluzone ® High-Dose End-of-Phase 2 meeting with the FDA expected in the first half of 2019 Pivotal Phase 3 clinical trial expected to initiate in...More>>

  • Jan 02, 2019

    GAITHERSBURG, Md. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will present at the 37th Annual J.P. Morgan Healthcare Conference . Presentation details are as follows: Date and time: Wednesday, January 9 , 3:00 p.m. – 3:25 p.m. P.T....More>>

  • Dec 04, 2018

    GAITHERSBURG, Md. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced the promotion of Jill Hoyt to Senior Vice President of Human Resources and Biegie Lee to Vice President of Information Technology. “I am thrilled to announce these two important management promotions;...More>>

Stock Quote